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Animal models of hypertension 
Since the discovery of endothelium-dependent r - 
laxation of vascular smooth muscle [13] vascular 
endothelium has been recognized as an important 
functional unit involved in the regulation of vascu- 
lar smooth-muscle tone. Relaxation results from 
release of a labile endothelium-derived r laxing fac- 
tor probably identical to nitric oxide (reviewed in 
[14, 25]). In addition to endothelium-derived r lax- 
ing factor, endothelium-derived vasoconstricting 
factors, with a characteristically slow onset and 
long duration of action, have also recently been 
demonstrated [16, 21, 53, 56]. In 1988 Yanagisawa 
et al. [76] isolated avasoconstrictive factor from the 
supernatant of cultured porcine endothelial cells 
and determined the amino acid sequence. It had 21 
amino acid residues with free amino- and carboxy- 
termini and four cysteine residues which formed 
two disulfide bonds (positions 1-15 and 3-11) 
(Fig. 1) with a molecular weight of 2492 and was 
named endothelin (subsequently endothelin-1). En- 
dothelin caused vasoconstriction of porcine right 
coronary artery segments with a concentration of
peptide evoking 50% of maximum effect (ECs0) of 
400 pM and a maximum tension comparable to 
KCl-induced contraction [76]. Sarafotoxin, the re- 
cently described venom of the burrowing asp 
Atractaspis engaddensis, has remarkable homology 
to endothelin isoforms 1-3 (Fig. 1) [31, 68]. En- 
dothelin is formed by cleaving 164 amino acids 
from the 203 amino acid prepro-endothelin [by 
means of specific endopeptidase(s)] resulting in big 
endothelin (39 amino acids). Big endothelin is sub- 
sequently converted to endothelin by means of an 
endothelin-converting e zyme (Fig. 2). 
Endothelin is now known to be a ubiquitous 
autacoid that is released from a number of en- 
Abbreviations: S HR = spontaneously hypertensive rat; ECso = 
concentration f peptide voking 50% of maximum effect; 
DOCA = deoxycorticosterone acetate 
dothelial cell sources, including porcine, but also 
from several renal cell lines, airway epithelial cells, 
and endometrial cells [36]. Endothelin gene tran- 
scription can be modulated in endothelial cells at 
the mRNA level by thrombin, adrenaline, an- 
giotensin II, arginine vasopressin, transforming 
growth factor-13 (TGF-I3), the calcium ionophores 
A23187 and ionomycin, phorbol esters, and shear 
stress; its release can be inhibited by nitric oxide or 
atrial natriuretic factor [42, 44]. The endothelin 
gene (encoding the 212 amino acid precursor pre- 
proendothelin) has been localized to human chro- 
mosome 6 and shown to contain five exons (nucle- 
otide sequences encoding the mature 21 amino acid 
endothelin-1 are contained within the second exon) 
[5]. Subsequently, three distinct human endothelin- 





Fig. 1. Amino acid sequences of endothelin-1, endothelin-2, en- 
dothelin-3, and sarafotoxin S6b (venom of the burrowing asp 
Atractaspis engaddensis). Hatched circles, amino acids where n- 
dothelin-2, endothelin-3 und sarafotoxin S6b differ from en- 
dothelin-1 
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Fig. 2. Biosynthesis of endothelin. Preproendothelin is cleaved 
by dibasic-amino acid pair-specific endopeptidases to yield big 
endothelin. Big endothelin is cleaved at Trp-Val by an endothe- 
lin-converting enzyme, resulting in endothelin 
by screening a human genomic DNA library under 
low hybridization stringency [26]. For the purpose 
of the present report endothelin-1 is designated as 
endothelin if not otherwise stated. 
Because ndothelin is the most potent vasocon- 
strictor known in man it has been hypothetized 
that endothelin may play an important role in hy- 
pertension. However, this question remains contro- 
versial even 5 years after isolation of the peptide. 
The present contribution briefly reviews data from 
in vitro and in vivo animal studies and studies in 
hypertensive patients in order to characterize the 
role of endothelin in hypertension. 
In vitro studies 
The marked vasoconstrictive effect of endothelin 
was first shown in porcine coronary arteries [76]. 
The maximum vasoconstrictive effect is compara- 
ble to that of high KC1 and the ECs0 of vasocon- 
striction in porcine coronary arteries is 400pM 
[76]. The vasoconstrictive effects of endothelin have 
been confirmed by a number of laboratories in ar- 
terial as well as venous vessels of different vascular 
beds and species (reviewed in [36, 42, 44]). Dohi et 
al. [10] have shown in mesenteric resistance arteries 
of the spontaneously h pertensive rat (SHR) that 
angiotensin II induced vascular endothelin produc- 
tion augments contractility. Threshold concentra- 
tions of endothelin have been shown to sensitize 
vascular smooth muscle to, for example, nore- 
pinephrine and serotonin [10, 67]. In line with these 
findings, Webb et al. [74] have demonstrated in rab- 
bit aorta that angiotensin II induced contractions 
can be inhibited with an endothelin receptor antag- 
onist (BQ123). 
In addition to the vasoconstrictive effects of en- 
dothelin, the peptide has been shown to be positive 
inotropic in isolated adult rat cardiomyocytes, with 
an ECs0 of 50 pM [27, 34]. The positive inotropic 
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effect of endothelin is mediated by sensitizing of 
cardiac myofilaments for calcium (in part due to 
endothelin-induced intracellular alkalosis) [27, 34, 
36]. Both endothelin-mediated (direct and indirect) 
vasoconstrictive effects and positive inotropic ef- 
fects might contribute to hypertension i animals 
or men. 
In vivo studies 
Yanagisawa et al. [76] were the first to demonstrate 
a marked increase in blood pressure after intra- 
venous administration of 1 nmol/kg endothelin in 
the rat. The sustained and long-lasting increase in 
blood pressure is preceded by a transient vasodi- 
latation most probably due to stimulation of re- 
lease of endothelium-derived r laxing facor, atrial 
natriuretic factor, or prostacyclin [42, 76]. Subse- 
quent studies howed dose-dependent i creases in 
blood pressure as well as a very long duration of 
action in comparison to angiotensin II (duration of 
action > 2 h after an intravenous bolus of 2 nmol/ 
kg) [45]. Calcium channel blockers antagonized ef- 
fectively the chronic phase of increase in blood 
pressure [45]. Mortensen et al. [49] demonstrated 
that chronic intravenous administration for 7 days 
causes a dose-dependent, reversible hypertension i  
rats. Captopril has been shown to control endothe- 
lin-induced hypertension, indicating that stimula- 
tion of the renin-angiotensin system may be in- 
volved in endothelin-induced hypertension [47]. 
When dietary sodium intake was manipulated, the 
same investigators demonstrated the endothelin-in- 
fusion model of hypertension to be salt dependent 
[48]. In prehypertensive Dahl-salt sensitive rats re- 
activity (isometric ontraction of vascular ings, in- 
crease in intracellular calcium) to endothelin was 
enhanced, and in hypertensive Dahl-salt sensitive 
rats medullary endothelin concentrations were in- 
creased in comparsion to salt resistant control ani- 
mals [18]. 
Plasma endothelin levels were surprisingly low- 
er in SHR and stroke-prone SHR in comparison to 
normotensive control rats, whereas deoxycorticos- 
terone acetate (DOCA) salt sensitive rats had nor- 
mal plasma endothelin levels [66]. Since the vascu- 
lar reactivity for endothelin was increased in DO- 
CA-salt sensitive rats, endothelin might play a role 
in sodium overload hypertension [66], possibly due 
to a decrease in plasma endothelin clearance [77]. 
Overall, there have been conflicting reports with 
regard to vascular sensitivity in different vascular 
beds and different strains of rats [42, 43]. 
In addition, there is good evidence that en- 
dothelin plays a role in central cardiovascular func- 
90 
tion. Increases in cerebrospinal endothelin levels 
are associated with pronounced hypertension and, 
on the other hand, phenylephrine-induced increase 
in blood pressure has been shown to cause a de- 
crease in cerebrospinal endothelin levels [50]. Very 
recent studies have investigated the effect of en- 
dothelin receptor A antagonists on blood pressure. 
Bazil et al. [3] demonstrated that the endothelin 
receptor A antagonist BQ123 inhibits the pressor 
response of endothelin-1 but not that of endothe- 
lin-3. Administration of BQ123 produced a mild 
antihypertensive effect in low- to normal-renin 
(DOCA-salt sensitive and SHR) but not in high- 
renin (two-kidney, one-clip, and aortic ligated rats) 
models of hypertension [3]. Nishikibe et al. [52] 
demonstrated antihypertensive efficacy of BQ123 
in stroke-prone SHR, a model of malignant hyper- 
tension, but not in normotensive controls or SHR. 
The results of Bazil et al. [3] and those of Batra et 
al. [2] suggest that not only endothelin receptor A
but also endothelin receptor B is involved in vaso- 
constrictive responses of endothelin. Pollock et al. 
[54] reported the interesting observation that 
BQ123 completely inhibits the pressor esponse of 
endothelin i Sprague-Dawley rats but is unable to 
affect he renal vasoconstrictor effects (decreases in
glomerular filtration rate, renal plasma flow, in- 
creases in renal vascular resistance). Endothelin 
had inconsistent effects on cardiac output in intact 
animals: transient increase in cardiac output and 
sustained ecrease in cardiac output in most re- 
ports in conscious or anesthetized rats, dogs, and 
cats [17, 22, 24, 30, 35, 38, 40, 46, 55, 73]. Cardiac 
output in the intact animal is influenced by many 
different factors, including endothelin-induced in- 
creases in peripheral resistance, direct positive in- 
otropic effects, hormonal effects of endothelin, and 
most importantly by constriction of the coronary 
arteries with subsequent ischemia. Neubauer et al. 
[51] demonstrated a parallel decrease of coronary 
flow and cardiac performance after administration 
of endothelin, using an isolated perfused rat heart. 
Despite a decrease in cardiac output and a marked 
increase of peripheral resistance isovolumic 
dp/dtma ×was slightly increased in anesthetized rats 
[35]. The effects of intravenous endothelin are not 
necessarily representative of the effects of endothe- 
lin in situ, where an autocrine/paracrine mode of 
action is predominant. Therefore a dysregulation f 
local endothelin secretion might nevertheless, by 
means of its direct positive inotropic effects, con- 
tribute to hypertension. 
Another important mechanism for endothelin- 
induced blood pressure regulation may be the well- 
known renal effects of endothelin: dose-dependent 
decreases in glomerular filtration rate, decreases in
renal plasma flow, and increases in filtration frac- 
tion in the anesthetized rat and anesthetized dog 
and in the isolated perfused rat kidney, whereas the 
fractional excretion of sodium remains either unaf- 
fected or is moderately increased epending on the 
dose of endothelin and the animal model employed 
[1, 28, 33, 41, 65]. Natriuresis induced by low doses 
of endothelin [20, 28] may be counterregulatory to 
the vasoconstrictive effects of endothelin. 
Judging from the above results, endothelin may 
play a role in hypertension (via its vasoconstrictive, 
positive inotropic effects, stimulation of aldos- 
terone secretion, and affecting central cardiovascu- 
lar function), and in the development of some forms 
of acute renal failure [33, 61]. At present, endothelin 
seems to contribute most to salt-sensitive forms of 
hypertension. 
Human studies 
Forearm blood flow is diminished in a dose-depen- 
dent manner with a long duration of action (in 
comparison to angiotensin II) after intra-arterial 
administration [8, 29], demonstrating that endothe- 
lin is a vasoconstrictor in man. Vierhapper et al. 
[71] demonstrated that exogenous endothelin caus- 
es hypertension in man. Yokokawa et al. [78] 
demonstrated that patients with malignant heman- 
gioendothelioma are hypertensive and have elevat- 
ed plasma endothelin levels. After surgery both 
blood pressure and plasma endothelin levels nor- 
malized. However, in one patient with recurrent 
disease both plasma endothelin levels and blood 
pressure increased again. Likewise, plasma en- 
dothelin levels are markedly elevated in women 
with preeclampsia/eclampsia and in patients with 
severe hypertension [11, 58, 69, 75]. In addition, 
endothelin may be involved in cyclosporine A in- 
duced hypertension since it has been shown that 
cyclosporine releases endothelin from human en- 
dothelial cells [7]. In rats treated chronically with 
cyclosporine an increased urinary excretion of en- 
dothelin has been shown [4]. A cyclosporine-in- 
duced increase in plasma endothelin levels in hy- 
pertensive cardiac transplant patients has been 
suggested [19], but the role of endothelin in cy- 
closporine-treated hypertensive patients has clearly 
to be investigated in further and more detailed 
studies. The endothelin receptor A antagonist 
BQ123 has been shown to be protective in cy- 
closporine-induced nephrotoxicity possibly by 
blocking the cyclosporine-induced vasoconstric- 
tion of the afferent arteriole [12, 37]. Finally, a role 
of endothelin i  the erythropoietin-induced hyper- 
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tension of, for example, dialysis patients has been 
put forward [6]. 
Measurement ofplasma endothelin levels in es- 
sential and secondary hypertension showed con- 
troversial results (normal or elevated concentra- 
tions) [9, 32, 57, 59, 60, 62, 70]. These differences 
may be due to different assays or patient samples. 
Lerman et al. [39] have shown that plasma en- 
dothelin levels are correlated with atherosclerosis, 
probably explaining part of the difference between 
different groups of hypertensive patients. In gener- 
al, the validity of plasma endothelin levels as a 
marker of action is questionable since endothelin is
thought to act predominantly in an autocrine/ 
paracrine fashion. Supporting this assumption, 
Wagner et al. [72] have recently demonstrated a 
markedly higher endothelin release in abluminal 
direction in cultured human endothelial cells. 
In addition to its cardiovascular effects (e.g. 
vasoconstriction/positive inotropy), its well-known 
(co-)mitogenic/atherogenic effe ts may be of impor- 
tance as causative factor or with regard to progres- 
sion of the disease [36]. Specifically, endothelin has 
been shown to promote proliferation of smooth- 
muscle cells, mesangial cells, and cardiomyocytes 
[23, 63, 64] - implicating a possible role of endothe- 
lin in the formation of atherosclerotic plaques as 
well as in cardiac growth and hypertrophy. Inter- 
estingly a role of endothelin i  primary pulmonary 
hypertension has recently been suggested [15]. 
Conclusions 
The demonstrated in vitro, in vivo, and human 
data are supportive of but in no way prove a role of 
endothelin in hypertension. Inhibitors of endothe- 
lin-converting enzyme and/or endothelin receptor 
antagonists are expected to contribute to the ulti- 
mate solution of this important question, especially 
when results become available during long-term 
treatment with these drugs. Short-term studies may 
not allow conclusions with regard to the role of 
endothelin in hypertension because of the known 
prolonged action of the peptide. Therefore the po- 
tential of endothelin receptor antagonists and/or 
endothelin-converting e zyme inhibitors as antihy- 
pertensive agents in human hypertension must be 
elucidated in further studies in experimental ni- 
mals and in man. 
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